Mechanism of Action of Natural Dipeptidyl Peptidase-IV Inhibitors (Berberine and Mangiferin) in Experimentally Induced Diabetes with Metabolic Syndrome

被引:3
|
作者
Suman, Rajesh Kumar [1 ]
Borde, Manjusha K. [2 ]
Mohanty, Ipseeta Ray [3 ]
Singh, Hemant Kumar [1 ]
机构
[1] Hind Inst Med Sci, Dept Pharmacol, Sitapur, Uttar Pradesh, India
[2] MGM Med Coll, Dept Pharmacol, Vashi, India
[3] MGM Med Coll, Dept Pharmacol, Navi Mumbai, Maharashtra, India
关键词
Berberine; diabetes; dipeptidyl peptidase-IV inhibitor; mangiferin; metabolic syndrome; INSULIN-RESISTANCE; METFORMIN; INFLAMMATION; SECRETION; BLOOD;
D O I
10.4103/ijabmr.ijabmr_115_23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Berberine (BER) and mangiferin are known natural dipeptidyl peptidase (DPP-IV) inhibitors. Hence, the study was designed to elucidate the mechanism of action of natural DPP-IV inhibitors (BER and MNG) in experimentally induced diabetes with metabolic syndrome.Aim: The aim of this study was to observe mechanism through which natural DPP-IV inhibitor works in diabetes with metabolic syndrome rat model.Materials and Methods: Wistar rats were fed high-fat diet for 10 weeks and challenged with streptozotocin (STZ) (40 mg/kg) at the 3rd week (high-fat diabetic control [HF-DC] group). After the confirmation of metabolic syndrome in the setting of diabetes, monotherapy (metformin [MET], vildagliptin [VIL], BER, and MNG) and combination (MET + VIL, MET + BER, and MET + MNG) therapy was orally fed to these rats from the 4th to 10th weeks.Results: Insulin resistance (IR) was seen in the HF-DC group as indicated by raised homeostasis model assessment of IR (HOMA-IR) in HF-DC group as compared with normal control (NC) groups. The treatment groups reduced IR as shown by a decrease in HOMA-IR as compared with HF-DC group rats. The marked reduction (P < 0.001) of beta-cell function was observed in the HF-DC group as a reduced level of HOMA for beta-cell function (HOMA-beta) was found as compared with the NC group. Increases in HOMA-beta as compared to the HFDC group were observed in the therapy groups. The treatment group significantly reduced cholesterol and atherogenic index. The treatment group showed significant preservation of beta-cell mass as per immunohistochemistry and significant anti-apoptotic activity as per Terminal Deoxyribonucleotidyl Transferase-Mediated dUTP Nick End Labeling assay report. The treated rats significantly (P < 0.05) reduced high-sensitivity C-reactive protein. Lipid peroxidation (thiobarbituric acid reactive substances) marker (P < 0.001) was significantly reduced in the treatment group.Conclusion: The natural DPP-IV inhibitors BER and MNG treatment showed beneficial effects on various components of metabolic syndrome.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 13 条
  • [1] Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
    Suman, Rajesh Kumar
    Mohanty, Ipseeta Ray
    Maheshwari, Ujwala
    Borde, Manjusha K.
    Deshmukh, Y. A.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 : 261 - 272
  • [2] Cardiometabolic Efficacy of Natural Dipeptidyl Peptidase- IV Inhibitors in Experimental Diabetes with Metabolic Syndrome Rats
    Suman, Rajesh Kumar
    Mohanty, Ipseeta Ray
    Borde, Manjusha K.
    Maheshwari, Ujjawala
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 116 : 15 - 15
  • [3] Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus
    Moore, Kevin B.
    Saudek, Christopher D.
    AMERICAN JOURNAL OF THERAPEUTICS, 2008, 15 (05) : 484 - 491
  • [4] Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes
    Singh, Anand-Krishna
    Jatwa, Rameshwar
    Purohit, Ashok
    Ram, Heera
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2017, 19 (10) : 1036 - 1045
  • [5] Dipeptidyl Peptidase-IV Inhibitors: An Evolving Treatment for Type 2 Diabetes from the Incretin Concept
    Chyan, Yau-Jan
    Chuang, Lee-Ming
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2007, 1 (01) : 15 - 24
  • [6] Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects
    Ahmed, Radwan H.
    Huri, Hasniza Zaman
    Al-Hamodi, Zaid
    Salem, Sameer D.
    Muniandy, Sekaran
    PLOS ONE, 2015, 10 (10):
  • [7] Changes in Gene Expression Profiles in Adult Rat Brain Structures after Neonatal Action of Dipeptidyl Peptidase-IV Inhibitors
    Zubkov, Eugene A.
    Zorkina, Yana A.
    Orshanskaya, Elena, V
    Khlebnikova, Nadezhda N.
    Krupina, Natalia A.
    Chekhonin, Vladimir P.
    NEUROPSYCHOBIOLOGY, 2018, 76 (02) : 89 - 99
  • [8] Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors
    Tahara, Atsuo
    Matsuyama-Yokono, Akiko
    Nakano, Ryosuke
    Someya, Yuka
    Hayakawa, Masahiko
    Shibasaki, Masayuki
    PHARMACOLOGICAL REPORTS, 2009, 61 (05) : 899 - 908
  • [9] Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV(DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective
    Kushwaha, R. N.
    Haq, W.
    Katti, S. B.
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (35) : 4013 - 4045
  • [10] Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors
    Atsuo Tahara
    Akiko Matsuyama-Yokono
    Ryosuke Nakano
    Yuka Someya
    Masahiko Hayakawa
    Masayuki Shibasaki
    Pharmacological Reports, 2009, 61 : 899 - 908